Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Show more
Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference PR Newswire SHELTON, Conn., Sept. 4, 2024 SHELTON, Conn., Sept. 4, 2024 /PRNewswire/ -- Intensity...
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire SHELTON, Conn., Aug. 8, 2024 First patient dosed in global randomized, Phase 3 study...
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma PR Newswire SHELTON, Conn., July 9, 2024...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.02 | 0.481927710843 | 4.15 | 4.32 | 3.92 | 11361 | 4.15059974 | CS |
4 | -0.08 | -1.88235294118 | 4.25 | 4.35 | 3.92 | 6591 | 4.17250329 | CS |
12 | -0.86 | -17.097415507 | 5.03 | 5.1 | 3.9139 | 11504 | 4.54325405 | CS |
26 | -0.51 | -10.8974358974 | 4.68 | 5.78 | 3.55 | 14548 | 4.65922326 | CS |
52 | -0.46 | -9.93520518359 | 4.63 | 11.44 | 2.0101 | 172865 | 6.65475302 | CS |
156 | -1.78 | -29.9159663866 | 5.95 | 11.44 | 2.0101 | 151515 | 6.60904832 | CS |
260 | -1.78 | -29.9159663866 | 5.95 | 11.44 | 2.0101 | 151515 | 6.60904832 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.